Castle Biosciences (CSTL) Other Operating Expenses (2019 - 2026)

Castle Biosciences has disclosed Other Operating Expenses across 8 years of filings, most recently posting $22.8 million for Q1 2026.

• Other Operating Expenses for Q1 2026 came in at $22.8 million, down 49.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $83.9 million (down 15.98% YoY), and the FY2025 annual result was $105.9 million, up 48.46% from the prior year.
• Other Operating Expenses came in at $22.8 million for Q1 2026 at Castle Biosciences, up from $20.6 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $44.7 million in Q1 2025 to a low of -$10.6 million in Q2 2022.
• The 5-year median for Other Operating Expenses is $16.1 million (2024), against an average of $16.2 million.
• Across the five-year window, Other Operating Expenses tumbled 368.53% in 2022 and jumped 225.35% in 2023, its largest moves.
• Castle Biosciences' Other Operating Expenses stood at $11.4 million in 2022, then rose by 28.5% to $14.7 million in 2023, then soared by 39.67% to $20.5 million in 2024, then increased by 0.33% to $20.6 million in 2025, then rose by 10.53% to $22.8 million in 2026.
• The last three Other Operating Expenses figures came in at $22.8 million (Q1 2026), $20.6 million (Q4 2025), and $21.0 million (Q3 2025), per Business Quant data.